GILD

Gilead Sciences
D

GILD

Arincen87/100B
166.870
USD
-0.73
(-0.44%)
Pre Open·168.040USD+1.170(+0.70%)
Last updated: · Delayed 15 min

Gilead Sciences balance sheet 1990–2026

Gilead Sciences had 6.44B USD in cash and short-term investments on 30 September 2026, against total debt of 26.23B USD: net debt of 19.79B USD.

Total assets Total liabilities Shareholders' equity

Click a line's chart icon in the table to add it to the chart; hover over it for a quick look.

Fiscal year
Latest
Q3 FY2026
FY2025
31 Dec 2025
FY2024
31 Dec 2024
FY2023
31 Dec 2023
FY2022
31 Dec 2022
FY2021
31 Dec 2021
FY2020
31 Dec 2020
FY2019
31 Dec 2019
FY2018
31 Dec 2018
FY2017
31 Dec 2017
FY2016
31 Dec 2016
Cash and equivalents
6.44B7.56B9.99B6.09B5.41B5.34B6.00B11.63B17.94B7.59B8.23B
Short-term investments
0.002.05B1.58B1.18B973.00M1.18B1.41B12.72B12.15B17.92B3.67B
6.44B9.61B11.57B7.26B6.39B6.52B7.41B24.35B30.09B25.51B11.90B
Cash growth
-12.41%-16.90%+59.25%+13.77%-2.07%-11.99%-69.58%-19.07%+17.95%+114.46%-18.57%
Receivables
5.01B4.91B4.42B4.66B4.78B4.49B4.89B3.58B3.33B3.85B4.51B
Inventory
1.90B1.77B1.71B1.79B1.51B1.62B1.68B922.00M814.00M801.00M1.59B
Other current assets
3.21B1.14B995.00M2.37B0.000.000.000.000.000.000.00
Total current assets
16.55B18.34B19.17B16.09B14.44B14.77B16.00B30.30B35.84B31.82B19.59B
Property, plant and equipment
5.95B5.61B5.41B5.32B5.48B5.12B4.97B4.50B4.01B3.30B2.87B
Long-term investments
0.002.97B0.001.16B1.25B1.31B502.00M1.49B1.42B11.18B20.49B
Goodwill and intangibles
21.74B25.29B28.26B34.77B37.21B41.79B41.23B17.90B19.86B21.26B10.14B
Goodwill
8.31B8.31B8.31B8.31B8.31B8.33B8.11B4.12B4.12B4.16B1.17B
Intangible assets
13.42B16.98B19.95B26.45B28.89B33.46B33.13B13.79B15.74B17.10B8.97B
Other non-current assets
4.90B4.85B3.77B4.79B4.80B4.96B5.71B7.44B2.56B2.72B3.49B
Total assets
51.41B59.02B59.00B62.13B63.17B67.95B68.41B61.63B63.68B70.28B56.98B
Accounts payable
934.00M715.00M833.00M550.00M905.00M705.00M844.00M713.00M790.00M814.00M1.21B
Deferred revenue
0.000.000.000.000.000.000.000.000.000.00202.00M
Short-term debt
2.42B2.81B1.82B1.80B2.27B1.52B2.76B2.50B2.75B2.75B0.00
Other current liabilities
4.03B3.86B3.82B3.92B3.62B1.43B1.45B736.00M555.00M455.00M196.00M
Total current liabilities
12.00B11.81B12.00B11.28B11.24B11.61B11.40B9.76B10.61B11.64B9.22B
Long-term debt
23.82B22.13B24.90B23.19B22.96B25.18B28.65B22.09B24.57B30.80B26.35B
Other non-current liabilities
2.32B2.06B2.13B3.32B5.09B5.74B6.23B7.12B6.96B7.35B2.05B
Lease obligations, current
0.000.000.000.000.000.000.000.000.000.000.00
Lease obligations, long-term
0.000.000.000.000.000.000.000.000.000.000.00
Total liabilities
38.45B36.41B39.75B39.38B41.96B46.89B50.19B38.98B42.14B49.78B37.61B
Common stock and paid-in capital
1.00M1.00M1.00M1.00M1.00M1.00M1.00M1.00M1.00M1.00M1.00M
Retained earnings
3.11B13.73B11.50B16.30B15.69B16.32B14.38B19.39B19.02B19.01B18.15B
Accumulated other comprehensive income
89.00M39.00M132.00M28.00M2.00M83.00M-60.00M85.00M80.00M165.00M278.00M
Shareholders' equity
13.04B22.70B19.33B22.83B21.24B21.07B18.20B22.53B21.39B20.44B18.89B
Minority interest
-84.00M-84.00M-84.00M-84.00M-31.00M-5.00M19.00M125.00M147.00M59.00M476.00M
26.23B24.94B26.71B24.99B25.23B26.70B31.40B24.59B27.32B33.54B26.35B
Net cash
-19.79B-15.32B-15.14B-17.72B-18.85B-20.18B-23.99B-241.00M2.77B-8.03B-14.45B
Working capital
4.55B6.53B7.17B4.81B3.21B3.16B4.60B20.54B25.23B20.19B10.37B
Book value per share
10.4218.0915.4018.1516.8316.6914.4117.6416.3515.5013.91
Tangible book value
-8.70B-2.59B-8.93B-11.94B-15.97B-20.72B-23.03B4.62B1.53B-817.00M8.74B
Tangible book value per share
-6.95-2.06-7.12-9.49-12.65-16.42-18.243.621.17-0.626.44
Current ratio
1.381.551.601.431.291.271.403.103.382.742.13
Debt to equity
2.011.101.381.091.191.271.731.091.281.641.39

Figures in USD at the end of each period. Net cash is cash and short-term investments less total debt; book value per share is on the diluted share count. The latest column is the most recent quarter.

Common questions about Gilead Sciences's cash and debt

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.